http://www.rxpgnews.com/ Medical News and Information Thu, 25 Oct 2007 07:48:36 PST en-us http://www.rxpgnews.com/cervicalcancer/New_vaccine_prevents_cervical_cancer_in_teens_4601_4601.shtml Cervical Cancer New research reported in the June issue of Clinical Pediatrics suggests that the possibility of preventing cervical cancer and other cancers caused by the human papilloma viruses (HPVs) will be a reality in the near future. Two new vaccines, one developed by Merck (approved in June 2006) and one developed by Smith Glaxo Kline (likely to be approved soon), target types of HPV known to have a link to cervical and other cancers. The new vaccines prevented the disease or reduced infection in over 90% of cases and was well tolerated. Sat, 01 Jul 2006 15:58:00 PST http://www.rxpgnews.com/cervicalcancer/New_vaccine_prevents_cervical_cancer_in_teens_4601_4601.shtml http://www.rxpgnews.com/cervicalcancer/Topotecan_for_Late-Stage_Cervical_Cancer_Approved_4472_4472.shtml Cervical Cancer The U.S. Food and Drug Administration has approved a combination of Hycamtin (topotecan hydrochloride) and cisplatin for use as the first drug treatment for women with late-stage cancer of the cervix when a physician determines that surgery or radiation therapy are unlikely to be effective. The approval includes a new indication for Hycamtin, which was approved in 1996 for treating ovarian cancer and in 1998 for small cell lung cancer. Fri, 16 Jun 2006 00:45:00 PST http://www.rxpgnews.com/cervicalcancer/Topotecan_for_Late-Stage_Cervical_Cancer_Approved_4472_4472.shtml http://www.rxpgnews.com/cervicalcancer/New_HPV_vaccine_is_100_percent_effective_4431_4431.shtml Cervical Cancer More than twenty years of collaborative research in the Georgetown lab of Dr. Richard Schlegel has resulted in a major medical breakthrough — the world’s first cancer vaccine. The vaccine's technology was generated by a team of Georgetown University researchers in the early 1990s and licensed for commercial development. On June 8, the Food and Drug Administration approved the vaccine, which scientists say could eliminate most new cases of cervical cancer worldwide. Called Gardasil, the vaccine blocks four strains of HPV, including two that give rise to nearly 75 percent of cervical cancer cases and two other strains that cause about 50 percent of genital warts. Sat, 10 Jun 2006 13:29:00 PST http://www.rxpgnews.com/cervicalcancer/New_HPV_vaccine_is_100_percent_effective_4431_4431.shtml http://www.rxpgnews.com/cervicalcancer/Vaccine_for_Cervical_Cancer_Approved_in_US_-_Overv_4423_4423.shtml Cervical Cancer FDA has now announced the licensure of Gardasil, the first vaccine for the prevention of cervical cancer, abnormal and precancerous cervical lesions, abnormal and precancerous vaginal and vulvar lesions and genital warts. Gardasil is a recombinant vaccine and is effective against HPV types 6, 11, 16 and 18, and is approved for use in females ages 9-26 years. Fri, 09 Jun 2006 02:05:00 PST http://www.rxpgnews.com/cervicalcancer/Vaccine_for_Cervical_Cancer_Approved_in_US_-_Overv_4423_4423.shtml http://www.rxpgnews.com/cervicalcancer/Quadrivalent_Human_Papillomavirus_HPV_Recombinant__4421_4421.shtml Cervical Cancer U.S. Food and Drug Administration (FDA) today approved a Quadrivalent Human Papillomavirus Recombinant Vaccine. It is the first and only vaccine to prevent cervical cancer and vulvar and vaginal pre-cancers caused by HPV types 16 and 18 and to prevent low-grade and pre-cancerous lesions and genital warts caused by HPV types 6, 11, 16 and 18 and is developed by Merck and will be marketed under trade name Gardasil. Fri, 09 Jun 2006 00:37:00 PST http://www.rxpgnews.com/cervicalcancer/Quadrivalent_Human_Papillomavirus_HPV_Recombinant__4421_4421.shtml http://www.rxpgnews.com/cervicalcancer/HPV_Vaccination_Predicting_Its_Effect_on_Cervical__3935_3935.shtml Cervical Cancer Each year, nearly 500,000 new cases of cervical cancer are diagnosed around the world, and more than 250,000 women die from the disease. Most of these cases occur in developing countries where there is no routine screening for precancerous lesions. By contrast, in developed countries, national screening programs have greatly reduced the number of women dying from this cancer—between 1955 and 1992 in the US, for example, cervical cancer deaths dropped by 74%. Wed, 05 Apr 2006 21:21:00 PST http://www.rxpgnews.com/cervicalcancer/HPV_Vaccination_Predicting_Its_Effect_on_Cervical__3935_3935.shtml http://www.rxpgnews.com/cervicalcancer/HPV_testing_is_more_sensitive_for_screening_cervic_3887_3887.shtml Cervical Cancer The current technique for screening for cervical cancer involves collecting cells by way of a pap smear and examining them under a microscope. Although this method has reduced cervical cancer in countries where it is regularly used, it has several weaknesses. A new study found that the test for human papillomavirus (HPV), which is present in almost all cervical cancers, is more sensitive than cytology (cell examination) in detecting cervical cancer. Mon, 03 Apr 2006 14:32:00 PST http://www.rxpgnews.com/cervicalcancer/HPV_testing_is_more_sensitive_for_screening_cervic_3887_3887.shtml http://www.rxpgnews.com/cervicalcancer/Community_s_income_status_predicts_cervical_screen_3064_3064.shtml Cervical Cancer African-American women living in communities with high poverty rates are less likely to be screened for cervical cancer, even after adjusting for other factors known to raise the risk of non-screening, such as older age, lower educational attainment, and smoking. Tue, 27 Dec 2005 17:17:00 PST http://www.rxpgnews.com/cervicalcancer/Community_s_income_status_predicts_cervical_screen_3064_3064.shtml http://www.rxpgnews.com/cervicalcancer/Novel_technique_to_remove_inoperable_cervical_spin_2792_2792.shtml Cervical Cancer UCSF surgeons are using a novel technique to remove tumors from the cervical region of the spine that were previously thought "inoperable." The procedure is reported in the November issue of Operative Neurosurgery. UCSF is the only medical institution in the United States where patients can undergo this surgery. Sun, 06 Nov 2005 11:23:00 PST http://www.rxpgnews.com/cervicalcancer/Novel_technique_to_remove_inoperable_cervical_spin_2792_2792.shtml http://www.rxpgnews.com/cervicalcancer/HPV_Vaccine_Prevented_100_Percent_of_Cervical_Pre-_2592_2592.shtml Cervical Cancer A quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine (GARDASILTM), an investigational vaccine from Merck & Co., Inc., prevented 100 percent of high-grade cervical pre-cancers and non-invasive cervical cancers (CIN 2/3 and AIS) associated with human papillomavirus (HPV) types 16 and 18 in a new phase III study. The analysis compared GARDASIL to placebo in women who were not infected with HPV 16 and 18 at enrollment and who remained free of infection through the completion of the vaccination regimen. Women were followed for an average of two years after enrollment. Fri, 07 Oct 2005 13:55:00 PST http://www.rxpgnews.com/cervicalcancer/HPV_Vaccine_Prevented_100_Percent_of_Cervical_Pre-_2592_2592.shtml http://www.rxpgnews.com/cervicalcancer/Clues_to_disappearing_precancers_uncovered_1787_1787.shtml Cervical Cancer New research sheds light on why cervical precancers disappear in some women and not in others. Scientists at the Johns Hopkins Kimmel Cancer Center report in the July 1 issue of Clinical Cancer Research that the reason many of these lesions persist is an unlikely mix of human papilloma virus (HPV) strain and a woman's individual immune system. Fri, 01 Jul 2005 12:57:00 PST http://www.rxpgnews.com/cervicalcancer/Clues_to_disappearing_precancers_uncovered_1787_1787.shtml http://www.rxpgnews.com/cervicalcancer/Failure_to_Screen_Pap_Test_Failure_Most_Common_Rea_1352_1352.shtml Cervical Cancer Increasing Pap screening adherence and improving the accuracy of Pap screening could reduce the incidence of invasive cervical cancer among women with access to screening and could afford earlier detection of cervical cancer, a new study concludes. Wed, 04 May 2005 17:26:00 PST http://www.rxpgnews.com/cervicalcancer/Failure_to_Screen_Pap_Test_Failure_Most_Common_Rea_1352_1352.shtml